Tags

Type your tag names separated by a space and hit enter

Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.
Neurodegener Dis Manag. 2019 04; 9(2s):1-2.ND

Abstract

Proceedings of an Almirall-sponsored satellite symposium held at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Berlin, Germany, 10 October 2018.

Authors+Show Affiliations

Center of Clinical Neuroscience, University Clinic Carl Gustav Carus Dresden, Dresden, Germany.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30657019

Citation

Ziemssen, Tjalf. "Tetrahydrocannabinol: Cannabidiol Oromucosal Spray for Treating Symptoms of Multiple Sclerosis Spasticity: Newest Evidence." Neurodegenerative Disease Management, vol. 9, no. 2s, 2019, pp. 1-2.
Ziemssen T. Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence. Neurodegener Dis Manag. 2019;9(2s):1-2.
Ziemssen, T. (2019). Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence. Neurodegenerative Disease Management, 9(2s), 1-2. https://doi.org/10.2217/nmt-2018-0048
Ziemssen T. Tetrahydrocannabinol: Cannabidiol Oromucosal Spray for Treating Symptoms of Multiple Sclerosis Spasticity: Newest Evidence. Neurodegener Dis Manag. 2019;9(2s):1-2. PubMed PMID: 30657019.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence. A1 - Ziemssen,Tjalf, Y1 - 2019/01/18/ PY - 2019/1/19/pubmed PY - 2020/8/19/medline PY - 2019/1/19/entrez KW - THC:CBD oromucosal spray KW - multiple sclerosis spasticity treatment KW - observational studies KW - randomized controlled trials SP - 1 EP - 2 JF - Neurodegenerative disease management JO - Neurodegener Dis Manag VL - 9 IS - 2s N2 - Proceedings of an Almirall-sponsored satellite symposium held at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Berlin, Germany, 10 October 2018. SN - 1758-2032 UR - https://www.unboundmedicine.com/medline/citation/30657019/Tetrahydrocannabinol:_cannabidiol_oromucosal_spray_for_treating_symptoms_of_multiple_sclerosis_spasticity:_newest_evidence_ L2 - https://www.futuremedicine.com/doi/10.2217/nmt-2018-0048?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -